Literature DB >> 29235195

Concise Review: Human Pluripotent Stem Cells to Produce Cell-Based Cancer Immunotherapy.

Huang Zhu1, Yi-Shin Lai1, Ye Li1, Robert H Blum1, Dan S Kaufman1.   

Abstract

Human pluripotent stem cells (PSCs) provide a promising resource to produce immune cells for adoptive cellular immunotherapy to better treat and potentially cure otherwise lethal cancers. Cytotoxic T cells and natural killer (NK) cells can now be routinely produced from human PSCs. These PSC-derived lymphocytes have phenotype and function similar to primary lymphocytes isolated from peripheral blood. PSC-derived T and NK cells have advantages compared with primary immune cells, as they can be precisely engineered to introduce improved anti-tumor activity and produced in essentially unlimited numbers. Stem Cells 2018;36:134-145.
© 2017 AlphaMed Press.

Entities:  

Keywords:  Adoptive cell therapy; Cancer immunotherapy; Human pluripotent stem cell; Natural Killer T cell; Natural Killer cell; T cell

Mesh：

Year:  2018        PMID： 29235195      PMCID： PMC5914526          DOI： 10.1002/stem.2754

Source DB:  PubMed          Journal:  Stem Cells        ISSN： 1066-5099            Impact factor:   6.277


  163 in total

Review 1.  Launching the T-cell-lineage developmental programme.

Authors:  Ellen V Rothenberg; Jonathan E Moore; Mary A Yui
Journal:  Nat Rev Immunol       Date:  2008-01       Impact factor: 53.106

2.  Early TCR expression and aberrant T cell development in mice with endogenous prerearranged T cell receptor genes.

Authors:  Thomas Serwold; Konrad Hochedlinger; Matthew A Inlay; Rudolf Jaenisch; Irving L Weissman
Journal:  J Immunol       Date:  2007-07-15       Impact factor: 5.422

3.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

Authors:  Guillaume Cartron; Laurent Dacheux; Gilles Salles; Philippe Solal-Celigny; Pierre Bardos; Philippe Colombat; Hervé Watier
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

Review 4.  Natural killer cells: the journey from puzzles in biology to treatment of cancer.

Authors:  Lakshmi Narendra Bodduluru; Eshvendar Reddy Kasala; Rajaram Mohan Rao Madhana; Chandra Shaker Sriram
Journal:  Cancer Lett       Date:  2014-12-12       Impact factor: 8.679

Review 5.  Challenges of cancer therapy with natural killer cells.

Authors:  Hans Klingemann
Journal:  Cytotherapy       Date:  2014-12-18       Impact factor: 5.414

6.  Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study.

Authors:  Lisbeth Barkholt; Evren Alici; Reka Conrad; Tolga Sutlu; Mari Gilljam; Birgitta Stellan; Birger Christensson; Hayrettin Guven; Niklas K Björkström; Gunnar Söderdahl; Kerstin Cederlund; Eva Kimby; Johan Aschan; Olle Ringdén; Hans-Gustaf Ljunggren; M Sirac Dilber
Journal:  Immunotherapy       Date:  2009-09       Impact factor: 4.196

Review 7.  Targeting natural killer cells in cancer immunotherapy.

Authors:  Camille Guillerey; Nicholas D Huntington; Mark J Smyth
Journal:  Nat Immunol       Date:  2016-08-19       Impact factor: 25.606

8.  Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity.

Authors:  Petter S Woll; Bartosz Grzywacz; Xinghui Tian; Rebecca K Marcus; David A Knorr; Michael R Verneris; Dan S Kaufman
Journal:  Blood       Date:  2009-04-13       Impact factor: 22.113

9.  Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac.

Authors:  Fei Xie; Lin Ye; Judy C Chang; Ashley I Beyer; Jiaming Wang; Marcus O Muench; Yuet Wai Kan
Journal:  Genome Res       Date:  2014-08-05       Impact factor: 9.043

10.  Advances in clinical NK cell studies: Donor selection, manufacturing and quality control.

Authors:  U Koehl; C Kalberer; J Spanholtz; D A Lee; J S Miller; S Cooley; M Lowdell; L Uharek; H Klingemann; A Curti; W Leung; E Alici
Journal:  Oncoimmunology       Date:  2015-11-11       Impact factor: 8.110
View more
  14 in total

1.  Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity.

Authors:  Huang Zhu; Robert H Blum; Ryan Bjordahl; Svetlana Gaidarova; Paul Rogers; Tom Tong Lee; Ramzey Abujarour; Gregory B Bonello; Jianming Wu; Pei-Fang Tsai; Jeffrey S Miller; Bruce Walcheck; Bahram Valamehr; Dan S Kaufman
Journal:  Blood       Date:  2020-02-06       Impact factor: 22.113

2.  Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity.

Authors:  Huang Zhu; Robert H Blum; Davide Bernareggi; Eivind Heggernes Ask; Zhengming Wu; Hanna Julie Hoel; Zhipeng Meng; Chengsheng Wu; Kun-Liang Guan; Karl-Johan Malmberg; Dan S Kaufman
Journal:  Cell Stem Cell       Date:  2020-06-11       Impact factor: 24.633

Review 3.  Enhancing a Natural Killer: Modification of NK Cells for Cancer Immunotherapy.

Authors:  Rasa Islam; Aleta Pupovac; Vera Evtimov; Nicholas Boyd; Runzhe Shu; Richard Boyd; Alan Trounson
Journal:  Cells       Date:  2021-04-29       Impact factor: 6.600

Review 4.  Induced pluripotent stem cells, a giant leap for mankind therapeutic applications.

Authors:  José Bragança; João André Lopes; Leonardo Mendes-Silva; João Miguel Almeida Santos
Journal:  World J Stem Cells       Date:  2019-07-26       Impact factor: 5.326

5.  Technical advances in NK cell-based cellular immunotherapy.

Authors:  Fang Fang; Wei Wang; Minhua Chen; Zhigang Tian; Weihua Xiao
Journal:  Cancer Biol Med       Date:  2019-11       Impact factor: 4.248

6.  Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting.

Authors:  Jiri Eitler; Natalie Wotschel; Nicole Miller; Laurent Boissel; Hans G Klingemann; Winfried Wels; Torsten Tonn
Journal:  J Immunother Cancer       Date:  2021-01       Impact factor: 13.751

Review 7.  Advances in Adoptive Cell Therapy Using Induced Pluripotent Stem Cell-Derived T Cells.

Authors:  Ratchapong Netsrithong; Methichit Wattanapanitch
Journal:  Front Immunol       Date:  2021-09-28       Impact factor: 7.561

8.  Directly reprogrammed natural killer cells for cancer immunotherapy.

Authors:  Han-Seop Kim; Jae Yun Kim; Binna Seol; Cho Lok Song; Ji Eun Jeong; Yee Sook Cho
Journal:  Nat Biomed Eng       Date:  2021-08-02       Impact factor: 25.671

Review 9.  Pluripotent Stem Cells: Cancer Study, Therapy, and Vaccination.

Authors:  Mojgan Barati; Maryam Akhondi; Narges Sabahi Mousavi; Newsha Haghparast; Asma Ghodsi; Hossein Baharvand; Marzieh Ebrahimi; Seyedeh-Nafiseh Hassani
Journal:  Stem Cell Rev Rep       Date:  2021-06-11       Impact factor: 5.739

10.  Umbilical Cord Blood and iPSC-Derived Natural Killer Cells Demonstrate Key Differences in Cytotoxic Activity and KIR Profiles.

Authors:  Benjamin H Goldenson; Huang Zhu; YunZu Michele Wang; Naveen Heragu; Davide Bernareggi; Alessa Ruiz-Cisneros; Andres Bahena; Eivind Heggernes Ask; Hanna Julie Hoel; Karl-Johan Malmberg; Dan S Kaufman
Journal:  Front Immunol       Date:  2020-10-15       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.